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Reproductive immunology research has long focused on T cell responses to paternal anti-
gens and tolerance mechanisms supporting fetal well-being. The participation of B cells
herein was not widely studied. Because of the fascinating immunological uniqueness of
pregnancy, it is however to be expected that such pleiotropic cells play a considerable role.
In fact, on the one hand B cells contribute toward pregnancy tolerance by secreting the
immunomodulatory cytokine IL-10 but on the other hand can seriously harm pregnancy
because of their capacity of producing autoantibodies. As for protective B cells, new evi-
dences in mouse models arise suggesting that IL-10 producing B cells, the so-called B10
cells, help in maintaining tolerance toward semi-allogenic fetal antigens. They may be also
important to fight danger signals at the fetal-maternal interface as, e.g., in the case of
infections with the aim to restore the disrupted fetal tolerance. In human pregnancies,
IL-10 producing B cells increase with pregnancy onset but not in the case of spontaneous
abortions. In vitro, they are able to suppressTNF-α production byT cells from pregnant indi-
viduals. Their generation and functionality will be discussed throughout this review article.
B cells can be deleterious to pregnancy as well. Aberrant B cell compartment is associated
with obstetric pathologies. In particular, the capacity of B2 cells to produce specific autoan-
tibodies or of B-1a B cells to secrete natural autoantibodies that can turn autoreactive will
be discussed herein.
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INTRODUCTION
The study of the mechanisms responsible for the paradoxical sur-
vival of the conceptus as an intra-uterine semi-allograft within
the genetically distinct female host has been an area of substantial
scientific devotion. Aspects, particularly those related to the role
of the maternal adaptive and innate immune response at a time
when the physiological unit of fetus and placenta is framed as well
as fertility problems, recurrent miscarriages, premature deliveries,
and pre-eclampsia have been widely studied.
B cells are a major component of the immune system thus
likely to be involved in maternal fetal immune tolerance. This
review will look back in time to the beginnings of B cell dis-
covery, their functional diverse subpopulations and provide the
reader with an au courant knowledge regarding their regulatory
and pathogenic role in pregnancy. Genuinely B cells were not
identified as cells but through their function of secreting anti-
bodies. In the late 1890s, Emil von Behring and Baron Kitasato
Shibasaburo described the appearance of protective antibodies in
blood in response to introducing foreign antigens into the body.
Kitasato and Behring demonstrated the value of antitoxin against
diphtheria and tetanus toxins by means of transferring graded
injections of blood serum from an animal infected with the dis-
ease to a non-immune animal, thus transmitting active humoral
immunity and preventing the disease (1). However which cell
types were involved in the generation of such antibodies was not
discovered for another half century. Murphy and Morton docu-
mented lymphocyte infiltration in immunized mice during the
process of rejecting inoculated cancer grafts, with either natural
or induced immunity. Per contra the destruction of lymphocytes
with repeated small doses of x-ray prior to introducing the cancer
graft led to a loss of natural or induced resistance toward inoc-
ulated cancer growth and the tumor graft grew more readily (2).
Following on Jerne postulated that an antigen binds to an antibody
by coincidence and upon binding further antibodies to that anti-
gen could be produced. Thus, this theory offered an explanation
for the presence of natural antibodies (3); based on this Burnet
published the theory of clonal selection in 1957. Herein, he pro-
posed that each lymphocyte carries specific immunoglobulins on
its cell surface, reflecting its specificity of the antibody that will
be synthesized upon antigen stimulation (4). Nossal and Leder-
berg confirmed this hypothesis during the following year (5). In
1956, B cells were first identified in chicken by Glick and Chang.
Their data demonstrated that the resection of the bursa of Fabri-
cius, called bursectomy, led to a suppressed antibody response
and in point of fact B cells did receive their name from this
bursa, the place of B cell origin in young birds, and not the term
bone marrow (BM) as one would believe because of their ori-
gin in humans (6). During the last decades, the key discoveries
included the unravelment of the immunoglobulin structure, the
antibody–antigen interaction, and the mechanisms involved in
the generation of antibody diversity. In particular, the knowledge
about the immunoglobulin structure triggered the development
of synthetic derived monoclonal antibodies. A breakthrough in
the field of specific gene modification in animals came with the
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isolation of embryonic stem cells and the discovery of homolo-
gous recombination (7, 8). Since then experimental models have
undergone significant technological development, beginning with
inbred mouse lines toward transgenic mouse models allowing for
B cell stock manipulation in the 1980s and gene knockout animals
in the 1990s (9).
A DISPLAY OF B CELLS AND B CELL SUBSETS
B lymphocytes are cells in the humoral immunity of the acquired
immune system and account for 5–15% of circulating lymphocytes
(10). Today, they are classically defined via the presence of endoge-
nous immunoglobulins. A common description is that of a cell
population expressing “clonally diverse cell surface immunoglob-
ulin receptors,” which recognize specific, antigenic epitopes (11).
In adult human subjects, as in all mammals, B lymphocytes
are continually formed in the BM from committed pluripotent
hematopoietic precursor cells (12). Preceding the BM is popu-
lated by hematopoietic stem cells originating from the fetal liver
(13). The earliest committed precursor of the B cell lineage is
the pro-B cell. Downstream, functionally immature B cells also
known as naive B cells (co-expressing IgM and IgD) exit the BM
and migrate to the spleen, where they differentiate through tran-
sitional stages into B1 cells (albeit not all B1 cells derive from the
BM) follicular B cells or marginal zone (MZ) B cells. B1 cells, inde-
pendently of their origin, are typically subdivided into B-1a and
B-1b cells (14).
The principal function of B lymphocytes is the production of
antibodies against microbial antigens. Naive B cells not yet exposed
to an antigen habitually recirculate secondary lymphoid tissues,
chiefly spleen and lymph node follicles in order to encounter anti-
gens. B cell activation,explicitly proliferation and differentiation, is
mediated through positive and negative regulation in gene expres-
sion upon antigen encounter. Eventually, most B cells differentiate
into antibody-secreting plasma cells while a small minority per-
sists as memory cells, the agent of lasting immunity. Crucially,
while first exposure to an antigen results in the generation of
IgM secreting plasma cells and memory B cells (primary immune
response), repeated activation of these memory cells by the same
antigen leads to the production of a large quantity of high-affinity,
monospecific class-switched IgG antibodies (secondary immune
response). The differences of these antibody categories and their
role in autoimmunity and pregnancy will be considered.
Beyond the widely recognized role of B lymphocytes in anti-
body production, B cells can also act as antigen presenting cells
(APCs) for the initiation of T cell immune responses, as demon-
strated in B cell depleted mice (15). B cells act as APCs by the
presence of a transmembrane receptor protein on their surface
known as the B cell receptor (BCR). Additionally, B cells can
regulate various T cell and DC functions through the secretion
of immunomodulatory cytokines (16–18). A novel but less well
understood concept describes a phenotypically distinct subset of
regulatory B cells to negatively regulate cellular immune responses
and inhibiting excessive, tissue specific inflammation (19).
Like other cells, B lymphocytes can be classified into subsets
according to their variation in development, anatomical location
and ability to migrate, surface marker expression and functional
characteristics. Their discovery has been facilitated by means of
phenotype recognition using multicolor flow cytometry (20, 21).
Two major B cell populations have been described; namely B1 cells
and B2 cells.
Follicular B cells and marginal zone B cells (MZ B cells) con-
stitute the B2 cell population. Together, they make up the chief
part of splenic B cells but differ among each other in anatomical
location, the follicles, and MZ, respectively. Follicular B cells are
produced postnatally from BM precursors and colonize the spleen,
lymph node follicles, and other peripheral lymphoid tissues. Upon
antigen exposure follicular B cells can undergo T cell dependent
maturation in form of immunoglobulin class switching, hyperso-
matic mutation, and differentiation into plasma and memory B
cells. Importantly, B2 cells are short-lived and proliferation relies
upon antigen stimulation. MZ B cells are innate-like lympho-
cytes essentially producing natural antibodies in the absence of
antigen stimulation and setting up rapid T cell-independent anti-
body responses against pathogenic antigens. In addition, they are
involved in antigen trapping, transport, and presentation (22). In
contrast to B2 cells, MZ B cells do not circulate but reside near the
marginal sinus of the spleen (23).
A functional distinct B cell population develops earlier in life
from hematopoietic stem cells present in the fetal liver and main-
tain their numbers by self-replenishment (24). As they develop
earlier than B2 cells during ontogeny, this population inher-
ited the term B1 cell. With regards to tissue location B1 cells
have been found to occupy different areas when comparing
human and mouse tissues. In the murine system, B1 cells pre-
dominantly localize to pleural and peritoneal spaces whereas in
human adults they primarily populate the peripheral blood (13,
25, 26). B1 cells have been readily identified in murine studies
and are distinguished by their expression of several surface mark-
ers CD45 (B220low), IgMhi, CD23−, CD43+, and IgDlow that are
not expressed by B2 cells (27, 28). B1 cells can be further sub-
divided into B-1a and B-1b cells based on distinct phenotypic
features within this group. By consensus B-1 cells expressing CD5
are known as B-1a cells and those lacking the expression of CD5
are known as B-1b cells (21, 29, 30). B1 cells are part of the innate
immune response and produce the majority of natural antibodies,
in particular IgM against a broad spectrum of infections (31–34).
These cells do not develop into memory B cells.
The most recently described subset of B2 cells is that of regu-
latory B cells. This unique population has been found to inhibit
excessive inflammatory responses that contribute to the develop-
ment of autoimmune disease. The main hallmark of regulatory
B cells is the production of IL-10, a potent anti-inflammatory
cytokine with pleiotropic immunoregulatory activities. Based on
their secretory function, they have been labeled B10 cells in the
mice and Breg in humans. However, this population exercises
their function through more than one mechanism for example the
secretion of TGF-β. They represent between 1 and 3% of splenic B
cells but much controversy exists regarding surface marker expres-
sion. It is fair to say that B10 do have a unique phenotype but
within this group are phenotypically distinct subsets. A further
regulatory B cell subset with a CD1dhiCD5+ phenotype had been
identified to secrete IL-10 and control T cell-dependent inflam-
matory responses (16). However, CD1dhi is expressed by various
hemopoietic-derived cells (35).
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ANTIBODY PRODUCTION
As stated earlier B2 cells are central players of humoral immunity
by giving rise to differentiated antibody-secreting plasma cells. The
antibody immune response is highly complex but as a simple out-
line once secreted, selectively produced antibodies recognize and
bind particular external antigens and aid their destruction. For all
that, there is a population of antibodies unable to form antigen–
antibody complexes due to a structural anomaly in form of an
oligosaccharide residue. These so-called asymmetric antibodies
compete with their precipitating counterpart by binding the same
antigen but are unable to activate effector immune mechanisms,
such as complement fixation and phagocytosis. Instead, they have
been speculated to function as blocking antibodies and thus may
provide protection to the antigen. This blocking property has been
demonstrated in previous studies (36).
Chiefly antibodies can be divided into five different classes
based on their structural variability, target specificity, and dis-
tribution. Per se all isotopes are categorized according to their
differences in the amino acid sequence in the constant region (Fc)
of the heavy chain. As well, they occur in two physical forms:
soluble antibodies and membrane-bound antibodies. Membrane-
bound immunoglobulins form the B cell antigen receptor complex
on B cells. B2 cell derived plasma cells secrete predominantly adap-
tive antibodies initially in form of IgM and subsequently in form of
high-affinity, somatically mutated IgG. Both are dependent upon
antigen stimulation. However, en masse IgM secretion is antigen-
independent, which brought about the concept of two distinct
types of IgM, natural IgM, and antigen-induced IgM respectively
(37). Natural IgM is mainly secreted by B1 cells and to a lesser
extent by MZ B cells in the complete absence of external antigenic
stimulation whereas antigen-induced IgM and IgG are mostly pro-
duced by B2 cells (38–43). Antibodies from both cell types have
been shown to be necessary and moreover act in concert to provide
full immune protection as demonstrated by Baumgarth et al. (44).
In contrast to their adaptive counterparts natural antibodies
are defined through their properties of low affinity and polyreac-
tivity. Typically, they are able to recognize cross-reactive epitopes
on encapsulated gram-positive bacteria, pathogenic viruses, apop-
totic cells, and oxidized low-density lipoproteins and promote
their clearance (31, 45). In this way, they provide immediate and
broad protection against pathogens within the naive host, making
them a crucial component of the humoral innate immune sys-
tem. Unfortunately, cross reactivity of B1 and MZ B cell derived
natural antibodies is not only skewed toward the recognition of
pathogenic antigens but also the recognition of self-antigens pro-
voking host cell destruction and ultimately autoimmunity. Thus,
it was tempting to speculate that B1 cells may play a central role
in the production autoantibodies (42, 46). However, natural anti-
body production is tightly regulated by the immune system and
these natural antibodies rarely enter germinal centers to undergo
affinity maturation. Hence, their potential for producing high-
affinity antibodies with harmful specificity against their own parts
is greatly restricted (45).
Surprisingly, several studies demonstrated that antibodies
involved in pathogenic immune deposits within the kidneys are
entirely of B2 cell origin (47). On that account, IgG antibodies
have been shown to function as dominant mediators for several
autoimmune diseases including systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) (48–50). The mechanisms
involved in generating autoantibodies are not fully understood.
However, through the process of gene segment rearrangement
the immune system is capable of generating a virtually unlim-
ited display of antibodies. Despite the establishment of multi-
ple checkpoints which negatively select B cells with self-reactive
antigen receptors, by some detrimental mechanism this genetic
rearrangement may give rise to autoreactive antibodies; subse-
quently interacting with self-antigens and contributing toward the
clinical picture of autoimmunity.
With reference to the production of natural IgM from B1 cells,
there is much debate regarding their protective and destructive
contribution toward autoimmune processes. Hayakawa and col-
leagues have demonstrated in 1999 that murine B1 cells are para-
doxically positively selected for the production of autoantibodies
(50). Mice deficient in serum IgM not only experienced a dimin-
ished response to pathogenic antigens. Moreover, the absence of
secreted IgM stimulated the development of IgG autoantibod-
ies (51). This was confirmed by Boes and colleagues in 2000 in
normal mice unable to secrete IgM and lupus-prone lympho-
proliferative (lpr) mice unable to secrete IgM. Here, lpr mice
developed elevated IgG autoantibodies and experienced more
severe glomerulonephritis owing to larger numbers of glomerular
immune complexes (52). These and subsequent data demonstrate
B1 cell-secreted IgM as a critical factor in hampering the develop-
ment and severity of autoimmunity possible by means of apoptotic
cell clearance (53, 54).
B1 cells have been implicated in the pathogenesis of acute
inflammation and chronic autoimmune diseases in murine and
human studies (55, 56). This was best witnessed in an SLE mice
model in which B1 cell depletion reduced the severity of lupus
autoimmune pathogenesis in (NZB×NZW) F1 mice (57). Fur-
ther studies have demonstrated a significant increase of murine
B1 cells as well as an increased production of self-reactive anti-
bodies in RA and SLE (28, 58, 59). Like murine B-1a cells, human
CD5+ B cells have been reported to produce autoantibodies in
form of IgM rheumatoid factor (60). As a number of studies do
support whereas others do not support the role of B1 cells involved
in the pathogenesis of autoimmune disease, this area remains
controversial.
IMMUNE REGULATORY FUNCTION OF B CELLS IN
AUTOIMMUNITY, CANCER, AND TRANSPLANTATION
The role of B cells in the pathogenesis of autoimmune diseases
extends beyond the production of autoantibodies. Rather B cells
are now well-recognized for their positive and negative regulatory
functions during immune responses. Newly described so-called
regulatory B cells possess the ability of negatively regulating cel-
lular immune responses and inflammation. A variety of cytokines
produced by regulatory B cell subsets have been reported, with IL-
10 being the most studied. The regulatory immune function was
first reported by Janeway and colleagues in 1996 in a B cell deficient
mice model of acute experimental autoimmune encephalomyelitis
(EAE) (61). Genetically B cell-deficient mice (IL-10−/−) developed
a persistent pro-inflammatory immune response and increased
severity of EAE in comparison to wild type mice (62). Although
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this particular B cell regulatory effect was not IL-10 dependent,
various mouse models have reinforced the importance of B cell
derived IL-10 in EAE and other human autoimmune disease (62,
63). As such B10 cells have been shown to suppress the progres-
sion of intestinal inflammation in inflammatory bowel disease
(IBD) and prevent the development of collagen-induced arthritis
in murine models (64–66).
Studies of B10 cells and human autoimmune diseases are
limited and their relevance in maintaining peripheral tolerance
remains unclear. One study demonstrated the presence and more-
over significantly increased production of B cell derived IL-10 in
untreated RA, SLE, and Sjögren’s syndrome patients compared to
controls (67). A different study defined a human B cell pheno-
type with regulatory capacities (67). CD19+CD24hiCD38hi B cells
isolated from human peripheral blood and stimulated with CD40
suppressed the differentiation of Th1 cells. This effect was partially
mediated by IL-10. In comparison, the same B cell population iso-
lated from the peripheral blood of SLE patients responded poorly
to CD40 stimulation, produced less IL-10 and in this way lost its
suppressive capacity.
In both murine and human models, the regulatory effects of
B cells are very likely mediated through the anti-inflammatory
effects of IL-10 and the ability of B cells to interact with patho-
genic T cells to reduce harmful immune responses. IL-10 effects
are mediated by multiple mechanisms such as the inhibition of the
pro-inflammatory cytokine TNFα production (68, 69). B10 cells
suppress Th1 differentiation and inhibit Ag-specific CD4
+CD25−
T cell proliferation (70). This key role of B cell derived IL-10
in controlling T cell mediated autoimmunity was supported in
several studies (67, 71, 72). A recent murine study identified a dif-
ferent IL-10 independent mechanism through which B cells can
regulate autoimmunity. Here, glucocorticoid-induced TNF ligand
(GITR ligand) expression by B cells was required to induce the
proliferation of Treg in promoting EAE recovery (63).
Although antitumor immunity is not well understood several
in vivo experiments have shown the regulatory action of B cells
in inhibiting immune response against tumors. In B cell knockout
(BKO) mice, the depletion of B cells enhanced tumor clearance
in Friend murine leukemia virus gag-expressing mouse EL-4 (EL-
4 gag) and D5 mouse melanoma whereas tumor progression in
wild type mice was uncontrollable (73). Similarly, EL-4 thymo-
mas, MC38 colon carcinomas, and B16 melanomas in IgM−/− B
cell-deficient mice exhibited spontaneous tumor regression or sig-
nificant delayed growth in comparison to wild type mice (74). It
has been speculated that IL-10 release from B cells inhibits CD8+
T cell memory development and INFγ production from CD8+ T
and natural killer (NK) cells. Both are important for the tumor
immune surveillance. Thus B cells can function as regulatory cells
in some tumor settings potentially through the decreased IL-10
production from B cell depleted mice.
GVHD is a pathological condition in which donor T cells
from the transplanted tissue initiate an immunologic attack on
the recipient’s cells. Host APCs particular DCs are crucial for the
stimulation of donor T cells and hence the induction of GVHD
(75). As previously stated B cells are also able to function as APCs
and given the regulatory action of B10 cells in autoimmunity and
cancer, their involvement in graft versus host disease has been
hypothesized and explored. Rowe and colleagues demonstrated
that B cell-deficient µMT mice receiving BM transplantation
demonstrated higher mortality rates due to acute GVHD than wild
type recipients (76). This seems to be directly linked to the ability of
B cells acting as APCs in reducing the proliferation of CD4+ T cells
as well as the production of pro-inflammatory cytokines within
the donor. Moreover, they have demonstrated that the mecha-
nism of B cells in suppressing GVHD is directly related to IL-10
as IL-10−/− mice developed more severe acute GVHD than recip-
ient mice in which B cells are wild type (76). Finally, although
most B cells are eliminated by total body irradiation preceding
graft insertion, IL-10 producing B cells appear to be more resistant
toward irradiation regimes. A recent cohort study aimed to iden-
tify immune parameters that would discriminate tolerant kidney
transplant patients from subjects receiving immunosuppression
with stable allograft function (77). This study found that tolerant
recipients displayed increased total B cell numbers and naive B
cells in peripheral serum and had an enhanced expression of three
B cell genes in comparison with recipients receiving immunosup-
pression. These results may also indicate a potential regulatory
role for B cells in transplantation tolerance although further stud-
ies are needed to identify whether such findings represent a cause
or consequence of tolerance.
B CELLS IN PREGNANCY
The concept of immune tolerance and the primary function of the
immune system protecting against pathogens becomes a much
more complex picture with view toward mammalian pregnancy.
During this period of time, the maternal immune system has the
double function of tolerating a semi-allogenic fetus, expressing
both maternal and paternal antigens, while maintaining the fight
against infection. This fine equilibrium between maternal fetal
tolerance and immune activation is orchestrated by multiple cel-
lular players. The role of B cells herein is poorly studied, especially
when taking into account the many studies dedicated to T cells in
pregnancy.
ANTIBODY PRODUCING B CELLS IN NORMAL PREGNANCY
AND DURING PREGNANCY COMPLICATIONS
We have previously described a population of IgG-type antibodies
that bind to antigens with a relative high-affinity but fail to initiate
host mechanisms facilitating the destruction of foreign antigens.
Since these asymmetric antibodies seem to provide protection for
antigens, it has been speculated that they may play a role in the
immunological aspects of protecting the fetus against maternally
derived symmetric, antipaternal antibodies at the fetomaternal
interface (78). Asymmetric antibodies have been identified in
human and other mammalian sera (79). Moreover, their pro-
duction increased considerably in maternal serum and placental
tissue during normal human pregnancy whereas their absence has
been associated with pregnancy failure (80–83). One mechanism
postulates that these antibodies block placental antigens in order
to prevent the immunological attack by maternal NK cells and
cytotoxic lymphocytes. Their secretion seems to be partially hor-
mone regulated (84). In contrast to the protective effect proposed
for asymmetric antibodies, natural antibodies facilitate pregnancy
complications.
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Pre-eclampsia (PE) is one of the leading causes of maternal
mortality and morbidity worldwide and affects between 6 and
8% of pregnancies (85). It is defined as new onset hypertension
presenting after 20 weeks gestation with significant proteinuria
and resolves post-delivery. Importantly, this condition not only
affects the mother but presents a high risk for the fetus in form of
intrauterine death, preterm delivery, and low birth weight. With
regards to the pathophysiology both immunological and genetic
contributory factors have been proposed in addition to preexist-
ing maternal diseases, i.e., chronic kidney disease and autoimmune
conditions such as systemic lupus erythematosis or antiphospho-
lipid syndrome. Pre-eclampsia is an abnormality of placentation,
in particular defective remodeling of maternal uterine spiral arter-
ies precipitating high resistance uteroplacental circulation leading
to insufficient placental and in this way fetal perfusion. Cells and
regulatory molecules have been implicated in the immunologi-
cal alterations established in the placental microenvironment of
patients with pre-eclampsia. One of the main differences in pre-
eclampsia is a shift toward Th1 responses and the production of
IFN-gamma of uncertain origin (86). Another mechanism is the
blockage of transmembrane receptors for two potent angiogenic
substances, vascular endothelial growth factor (VEGF) and pla-
cental growth factor (PlGF). Fms-like tyrosine kinase-1 (sFlt-1)
has been identified to block these receptors and was found in
high concentrations in pre-eclampsia (87–90). This endothelial
dysfunction was rescued by administration of exogenous VEGF
and PlGF in vitro studies. Furthermore heme oxygenase-1 (HO-
1), an anti-inflammatory enzyme, able to inhibit sFlt-1 release
has been found to be decreased in women who later developed
pre-eclampsia. This is supported by data from animal models
where it could be shown that HO-1 deficiency is related to uterine
growth restriction and development of hypertension at midpreg-
nancy. This seems to be dependent on the number of uterine NK
cells. A HO-1 metabolite, carbon monoxide, can rescue this PE-
like phenotype when applied continuously during implantation
and placentation at low doses (91, 92). A different mechanism
suggested autoantibodies against the vascular angiotensin II recep-
tor type 1 (AT1) to account for disease manifestation. In 1999,
Wallukat and colleagues were first to report the presence of cir-
culating autoantibodies (AT1-AA) against the AT1 receptor in
patients with pre-eclampsia, suggesting their involvement in ges-
tational hypertension (93). The current understanding of AT1-AA
and their involvement in pre-eclampsia was recently reviewed by
Herse and LaMarca (94). As described earlier, CD19+CD5+B-1a
B cells are a major source of natural and polyreactive antibod-
ies. Recent evidence comes from Jensen and colleagues, as they
detected a dramatically increased CD19+CD5+B-1a B cell count
in peripheral blood of pre-eclamptic patients in comparison to
controls having normal pregnancies. The same cells were fur-
ther detected in the placenta of pre-eclamptic but not normal
pregnancies. This process seems to be driven by higher chori-
onic gonadotropin (hCG) levels present in the serum and pla-
centa of patients with pre-eclampsia and is supported by the
fact that 95% of CD19+CD5+ cells express the hCG receptor
(hCGR) and expand on hCG stimulation in vitro cultures. Most
importantly, isolated CD19+CD5+ cells produce autoantibodies
against angiotensin II type 1 receptor (95).
Lately, we have learned that pre-eclamptic women exhibit com-
ponents similar to various chronic inflammatory diseases, such as
elevated TNF-alpha, autoantibodies, and autoimmune associated
T cells and cytokines (96–99). Recent studies focused predomi-
nantly on the role of the agonistic autoantibody to the angiotensin
II type 1 receptor (AT1-AA) to account for much of the pathophys-
iology of pre-eclampsia (100–102). Of those several demonstrated
that infusion of purified rat AT1-AA into normal pregnant rats
increased blood pressure, the antiangiogenic factor sFlt-1 and
sEndoglin (103, 104). To further demonstrate, the important role
for B cells and endogenously generated AT1-AA in mediating
hypertension in response to placental ischemia, La Marca and col-
leagues have proposed a model of B cell depletion to suppress
endogenously generated AT1-AA. Rituximab, a chimeric murine-
human monoclonal antibody against the CD20 antigen located
on pre-B, immature, and mature B cells, was used to induce B cell
depletion in normal pregnant and reduced uterine perfusion pres-
sure (RUPP) rats (104). RUPP rats treated with rituximab exhib-
ited less blood pressure increases in response to induced placental
ischemia (105). This data provides potential insight into adverse
pregnancy outcomes in humans and can provide a new approach
to the treatment of pregnancy failure. As such a recent case report
has described a successful pregnancy after rituximab treatment in
a patient with a history of in vitro fertilization (IVF) failures and
positive anti-cardiolipin antibody (ACA). Following a course of
rituximab, the patient’s ACA became negative and she successfully
conceived with IVF treatment (106). Rituximab destroys B cells
that have CD20 on their surfaces, normal, and malignant respec-
tively. CD20 is not expressed on stem cells and most plasma cells,
thus B cell regeneration is possible and immunoglobulin synthe-
sis by plasma cells is not affected after treatment with anti-CD20
antibody (107, 108). It has been used to treat diseases, which are
characterized by excessive numbers of B cells, overactive B cells, or
dysfunctional B cells. This includes several autoimmune diseases,
B cell malignancies, and transplant rejection (109).
B10/Breg CELLS IN PREGNANCY
As the fetus is semi-allogeneic to its mother, it is reasonable to
assume that the maternal immune response is a key determinant in
pregnancy success and failure. In normal pregnancy, immunolog-
ical adaptations are in place to protect the fetus from the maternal
immune system. Failure in the accommodation of such mecha-
nism could lead to sporadic and recurrent pregnancy loss. Recur-
rent miscarriage is an important complication of human gestation,
affecting approximately 1% of the population (110). It is classi-
cally defined as a loss of three or more consecutive and clinically
recognized pregnancies within the first trimester. Although not
fully understood the underlying etiology of recurrent pregnancy
is either embryological or maternal driven and can be divided into
anatomical, genetic, endocrine, infectious, environmental, throm-
bophilic, and immunological factors (111). Focusing on the latter
one mechanism postulated is the recognition of paternal antigens
at the fetoplacental unit by the maternal immune system, resulting
in a pro-inflammatory immune response and fetal rejection (112).
The concept that B10/Breg cells immunomodulate inflammatory
processes and participate in the maintenance of tolerance through
IL-10 gave rise to the idea that they may control inflammatory
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FIGURE 1 | B cell behavior during pregnancy. Pregnancy factors promote
the generation of asymmetric antibodies that protect placental antigens from
immune reactions. In pre-eclampsia, B-1a B cells can turn autoreactive and
secrete antibodies against the angiotensin receptor 1. In patients with
autoimmune disorders, it is possible that B cells secrete more autoantibodies
and endanger the gestation. A newly described B cell type, the so-called
regulatory B cells, produces IL-10 and is proposed to positively influence
pregnancy by hindering Th1 immune responses.
processes in pregnancy and are important in the immunological
adaptations leading to the survival of the fetus.
While researchers have reported a considerable expression of
IL-10 in the decidua and placenta in mice and humans, IL-10 is
not crucial for the completion of successful allogeneic pregnancies
as demonstrated in breeding experiments of IL-10-null mutant
(Il10−/−) mice (113–115). However, IL-10 serves an important
role in protecting pregnancy from the adverse effects of inflamma-
tory stress during gestation. This became evident in rodent studies
using lipopolysaccharide (LPS) to induce pregnancy loss. Il10−/−
animals demonstrated high incidences of miscarriage whereas
administration of equal doses of LPS did not affect pregnancies in
the control group (116). Concomitantly, administration of recom-
binant IL-10 reversed the harmful effects of injected LPS (117). Of
further significance was a report by Chaouat and colleagues uti-
lizing CBA×DBA/2 mice. CBA×DBA/2 mating combinations
express high rates of spontaneous fetal resorption accompanied by
increased levels of local pro-inflammatory cytokines. This is likely
to result from a local defect in the IL-10 production as IL-10 levels
in placenta and decidua in pregnancies of CBA/J×DBA/2J mating
combination have been shown to be exceptionally low. Exogenous
administration of recombinant IL-10 significantly reduced LPS-
induced fetal loss in CBA/J×DBA/2J but did not change outcomes
of Il10+/+mice (118). Conversely, anti-IL-10 antibodies increased
resorption rates in this group (119). Furthermore in the remain-
ing viable fetuses IL-10 deficiency predispose to growth restriction
and a progressive decline in fetal weight in the presence of LPS.
This was not observed in Il10+/+ mice treated with LPS (118).
Several mechanisms have been argued through which IL-
10 may accomplish pregnancy preservation from LPS-induced
pathologies. IL-10 is well known to inhibit the synthesis of pro-
inflammatory cytokines specifically TNF-alpha from monocytes
and macrophages in autoimmunity (120). Consequent cytokine
profile analysis of maternal serum and gestational tissue follow-
ing LPS injections showed elevated pro-inflammatory cytokine
levels in Il10−/− mice compared with tissues from Il10+/+ mice.
Significantly raised levels were measured for TNF-α, IL6, IL1A,
and IL12p40 with TNF-α most dramatically affected by IL-10
deficiency (118, 121). Further evaluation of TNF-α in mediating
the adverse effects of IL-10 deficiency in pregnancy using etaner-
cept, a TNF inhibitor, Robertson and colleagues demonstrated a
partial reduction in fetal loss in IL-10−/−mice treated with etaner-
cept (118). Another study has reported an important association
between fetal resorption in IL-10 deficient mice with a signifi-
cant rise in uterine NK cell cytotoxicity and placental invasion.
Pregnancies in LPS-treated IL-10 deficient mice could be res-
cued through depleting uNK cells, IL-10 administration, or TNF-
alpha reversal. These results suggested an immune mechanism
of fetal destruction by which uNK cells mediate inflammation
in the absence of IL-10 whereas a regulatory cross-talk between
IL-10 and uNK cells contributes toward a positive pregnancy
outcome (122).
As discussed earlier, an important source of IL-10 comes from
regulatory B cells. In our own studies, we have established that
splenic B10 cells increased in frequency during normal murine
pregnancy (NP). This B10 cell expansion was not evident in the
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non-pregnant and abortion prone (AP) group, both of which
demonstrated comparable low levels. Similarly on measuring IL-
10, we demonstrated an increase in IL-10 production in NP
compared to non-pregnant mice. Again this augmentation was
not observed in AP mice. Addressing the participation of B10
cells in establishing pregnancy tolerance, we further identified
that the transfer of B10 cells from NP mice into AP animals on
day 0 of pregnancy was sufficient to prevent fetal rejection (123).
One possible mechanism of IL-10 action is through DCs, as they
abundantly express the IL-10 receptor (IL-10R) and can alter the
functionality of other immune cells. IL-10 inhibits the maturation
process of monocyte derived DCs into efficient IL-12 secreting
APCs consequently inhibiting their capacity to present antigens
to T cells to activate them and induce the differentiation of naïve
T cells to Th1 cells (124). This mechanism may be applicable for
pregnancy as suggested by our data. We proved that IL-10 kept
DCs in an immature state whereas DC maturation continued in
the presence anti IL-10 antibody. Furthermore transferring B10
cells from NP into AP females was associated with decreased num-
bers of mature DCs and an augmentation of CD4+Foxp3+Treg.
Foxp3+ regulatory T cells play a central role in sustaining maternal
fetal immune tolerance and immature DCs are efficient inducers
of Tregs in pregnancy (125). Overall the anti-inflammatory prop-
erties of B10 cells can provide a new approach to the treatment of
spontaneous abortion due to immune mediated fetal rejection.
SUMMARY
B cells are pleiotropic components of the immune system and are
at the interface of innate and adaptive immunity. Their role during
pregnancy is rather poorly studied. It is however known that preg-
nancy factors promote the generation of asymmetric antibodies
that protect the fetus from immune reactions. In pre-eclampsia,
B-1a B cells can turn autoreactive and secrete antibodies against the
angiotensin receptor 1. In patients with autoimmune disorders, it
is possible that B cells secrete more autoantibodies and endanger
the gestation. A newly described B cell type, the so-called regula-
tory B cells, produces IL-10 and is proposed to positively influence
pregnancy by hindering Th1 immune responses. This is resumed
in Figure 1.
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